Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:ANNX NASDAQ:IVA NASDAQ:SLRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.74+3.9%$4.51$3.08▼$5.38$900.77M0.622.96 million shs2.90 million shsANNXAnnexon$5.89-9.4%$5.37$2.03▼$7.18$1.06B1.165.15 million shs7.71 million shsIVAInventiva$4.52+1.1%$4.37$2.85▼$7.98$928.45M0.721.62 million shs869,105 shsSLRNAcelyrin$2.27$2.27$1.95▼$2.66$229.17M1.071.09 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+3.95%-7.78%+7.97%+0.42%+51.44%ANNXAnnexon-9.38%-0.84%+30.31%-9.94%+145.42%IVAInventiva+1.12%-0.22%+26.26%-20.28%+36.14%SLRNAcelyrin0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.74+3.9%$4.51$3.08▼$5.38$900.77M0.622.96 million shs2.90 million shsANNXAnnexon$5.89-9.4%$5.37$2.03▼$7.18$1.06B1.165.15 million shs7.71 million shsIVAInventiva$4.52+1.1%$4.37$2.85▼$7.98$928.45M0.721.62 million shs869,105 shsSLRNAcelyrin$2.27$2.27$1.95▼$2.66$229.17M1.071.09 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+3.95%-7.78%+7.97%+0.42%+51.44%ANNXAnnexon-9.38%-0.84%+30.31%-9.94%+145.42%IVAInventiva+1.12%-0.22%+26.26%-20.28%+36.14%SLRNAcelyrin0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.00Hold$5.005.49% UpsideANNXAnnexon 2.50Moderate Buy$17.80202.21% UpsideIVAInventiva 3.09Buy$16.56266.27% UpsideSLRNAcelyrin 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLRN, IVA, ABUS, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026IVAInventiva Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight7/15/2026ANNXAnnexon Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $25.007/13/2026ANNXAnnexon Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.004/21/2026IVAInventiva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ABUSArbutus Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$14.08M66.50N/AN/A$0.40 per share11.85ANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AIVAInventiva$5.07M185.18N/AN/A($0.22) per share-20.55SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$33.50M$0.835.71N/AN/A83.95%129.32%112.24%8/5/2026 (Estimated)ANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)IVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/A9/25/2026 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/ALatest SLRN, IVA, ABUS, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ANNXAnnexon-$0.23N/AN/AN/A$6.50 millionN/A8/5/2026Q2 2026ABUSArbutus Biopharma-$0.02N/AN/AN/A$0.70 millionN/A5/13/2026Q1 2026ABUSArbutus Biopharma-$0.03$0.87+$0.90$0.87$0.75 million$179.13 million5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AANNXAnnexonN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A54.2654.26ANNXAnnexonN/A6.356.35IVAInventivaN/A3.163.16SLRNAcelyrinN/A7.157.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ANNXAnnexonN/AIVAInventiva19.06%SLRNAcelyrin87.31%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma19.90%ANNXAnnexon10.31%IVAInventiva32.00%SLRNAcelyrin13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90197.54 million158.23 millionOptionableANNXAnnexon60163.84 million146.95 millionOptionableIVAInventiva100207.71 million141.24 millionNot OptionableSLRNAcelyrin135100.95 million86.68 millionNo DataSLRN, IVA, ABUS, and ANNX HeadlinesRecent News About These CompaniesACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesMay 13, 2025 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with AlumisMay 6, 2025 | globenewswire.comAcelyrin urges stockholders to vote for proposed merger with AlumisMay 2, 2025 | finance.yahoo.comACELYRIN Reiterates Benefits of Value-Maximizing Combination with AlumisMay 1, 2025 | globenewswire.comAlumis and ACELYRIN Announce Amended Merger AgreementApril 21, 2025 | globenewswire.comACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRNApril 16, 2025 | businesswire.comAlumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deAlumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLDMarch 30, 2025 | morningstar.comMInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of StockMarch 20, 2025 | insidertrades.comAcelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comACELYRIN Adopts Limited-Duration Stockholder Rights PlanMarch 13, 2025 | globenewswire.comAcelyrin: Potential Buyout Led By Concentra BiosciencesMarch 12, 2025 | seekingalpha.comIs Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | finanznachrichten.deAcelyrin says Concentra indication not expected to result in superior proposalMarch 4, 2025 | markets.businessinsider.comAcelyrin falls as Acelyrin reaffirms deal commitmentMarch 4, 2025 | msn.comAcelyrin, Alumis reaffirm strategic, financial rationale of proposed mergerMarch 4, 2025 | markets.businessinsider.comACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | globenewswire.comACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerMarch 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIQM's Nasdaq Debut Could Change the Quantum Race for D-WaveBy Nathan Reiff | July 10, 2026Carnival's Second Quarter: Is the Stock Still Complicated?By Peter Frank | June 25, 2026USA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBy Peter Frank | June 22, 2026Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already ThereBy Jessica Mitacek | July 8, 2026Abivax: Wall Street Catches Up to the DataBy Chris Markoch | July 7, 2026SLRN, IVA, ABUS, and ANNX Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.74 +0.18 (+3.95%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$4.74 +0.00 (+0.11%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Annexon NASDAQ:ANNX$5.89 -0.61 (-9.38%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$5.84 -0.05 (-0.81%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Inventiva NASDAQ:IVA$4.52 +0.05 (+1.12%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$4.52 0.00 (0.00%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
